Obesity Treatments
4 articles on Obesity Treatments, written by Shotlee and medically reviewed for clinical accuracy.
China's Pharma Dominance Is Just Beginning
The pharmaceutical world is shifting: China has surged past the US in early-stage drug research, with programs jumping over 600% since 2015. This rapid growth promises cheaper, innovative treatments like advanced obesity drugs potentially better than Ozempic—but raises questions on access and geopolitics for patients worldwide.
5 min read
Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
5 min read
Roche Allocates $100 Million in Structure Licensing Pact to Bolster GLP-1 Standpoint
Roche has invested $100 million in a licensing agreement with Structure Therapeutics to protect its GLP-1 portfolio from patent challenges. The deal covers CT-996, an oral GLP-1 medication acquired from Carmot, and includes royalties on future sales. Analysts highlight how this move reinforces Structure's strong intellectual property in GLP-1 agonists.
3 min read
Let Them Eat Cake: A Solution for Obesity Exists, Yet Only the Affluent Can Access It
Scientific advancements in obesity treatment have revolutionized weight management, but financial barriers ensure these benefits primarily serve the rich. From costly medications to inaccessible surgeries, the struggle reveals deep societal inequalities. Addressing this requires structural changes to make health equitable for all.
5 min read